Docetaxel Plus Garlic in Treating Patients With Locally Advanced or Metastatic Breast Cancer

This study has been completed.
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00079170
First received: March 8, 2004
Last updated: June 18, 2013
Last verified: October 2006
  Purpose

RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether garlic supplements affect the ability of docetaxel to kill tumor cells.

PURPOSE: This clinical trial is studying how well giving docetaxel together with garlic works in treating patients with locally advanced or metastatic breast cancer.


Condition Intervention
Breast Cancer
Dietary Supplement: garlic
Drug: docetaxel

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment
Official Title: A Pilot Study to Evaluate the Influence of Garlic on the Pharmacokinetics of Docetaxel in Patients With Metastatic Breast Cancer

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Study Start Date: January 2004
Study Completion Date: October 2007
Detailed Description:

OBJECTIVES:

Primary

  • Determine the clinical pharmacokinetic behavior of docetaxel with and without garlic tablets in patients with locally advanced or metastatic breast cancer.
  • Determine the toxicity of this regimen in these patients.

Secondary

  • Determine the incidence of enzyme and transporter polymorphism in patients treated with this regimen.

OUTLINE: This is a pilot, open-label study.

Patients receive docetaxel IV over 60 minutes on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. On days 5-17 of course 1, patients receive oral garlic twice daily. Patients have the option of continuing garlic tablets as long as they remain on study.

PROJECTED ACCRUAL: A total of 9-12 patients will be accrued for this study within 6 months.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically confirmed adenocarcinoma of the breast
  • Incurable, locally advanced or metastatic disease for which therapy with docetaxel is a reasonable option
  • No documentation of progressive disease while on docetaxel within the past 2 months
  • Brain and/or leptomeningeal metastases are allowed only if all of the following criteria are met:

    • Asymptomatic on neurological examination, including after definitive radiotherapy
    • No corticosteroid therapy to control symptoms
    • Stable lesions
  • Hormone receptor status:

    • Not specified

PATIENT CHARACTERISTICS:

Age

  • 18 and over

Sex

  • Male or female

Menopausal Status

  • Not specified

Performance status

  • ECOG 0-2

Life expectancy

  • At least 12 weeks

Hematopoietic

  • Neutrophil count ≥ 1,200/mm^3
  • Platelet count ≥ 100,000/mm^3

Hepatic

  • Bilirubin normal
  • ALT and AST ≤ 2 times ULN (3 times ULN with liver metastases)

Renal

  • Creatinine normal OR
  • Creatinine clearance ≥ 60 mL/min

Cardiovascular

  • No symptomatic congestive heart failure
  • No unstable angina pectoris
  • No cardiac arrhythmias

Gastrointestinal

  • No known gastric emptying disorders
  • No persistent diarrhea

Other

  • No uncontrolled diabetes mellitus
  • No active infection
  • No prior grade 3 or 4 allergic reaction attributed to compounds of similar biological composition to garlic, docetaxel, or Tween 80
  • No other concurrent uncontrolled medical condition that would preclude study participation
  • No psychiatric illness or social situation that would preclude study compliance
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective barrier contraception
  • Must be able to ingest oral medication
  • Lactic dehydrogenase ≤ 2 times ULN

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • At least 3 weeks since prior immunotherapy
  • No concurrent immunotherapy

    • Trastuzumab (Herceptin®) allowed after the first course of therapy at the discretion of the primary physician
  • No concurrent pegfilgrastim

Chemotherapy

  • See Disease Characteristics
  • At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
  • No other concurrent chemotherapy

Endocrine therapy

  • See Disease Characteristics
  • At least 2 weeks since prior hormonal therapy
  • No concurrent hormonal therapy
  • No concurrent megestrol during the first course of study treatment

Radiotherapy

  • See Disease Characteristics
  • At least 3 weeks since prior radiotherapy
  • No concurrent radiotherapy

Surgery

  • Not specified

Other

  • More than 30 days (or 5 half-lives) since prior investigational therapy
  • No concurrent aprepitant (Emend®)
  • No concurrent or oral tetrahydrocannabinol (Marinol®) during the first course of study treatment
  • No concurrent combination antiretroviral therapy for HIV-positive patients
  • No other concurrent investigational or anticancer medications
  • No concurrent antiepileptic therapy
  • No concurrent immunosuppressants
  • No other concurrent herbal therapies during the first month of study participation
  • No concurrent grapefruit juice during the first month of study participation
  • No concurrent administration of the following:

    • Alprazolam
    • Cyclosporine
    • Diltiazem
    • Dofetilide
    • Erythromycin
    • Fluvoxamine
    • Itraconazole
    • Ketoconazole
    • Quinine
    • Hypericum perforatum (St. John's wort)
    • Tacrolimus
    • Theophylline
    • Warfarin
    • Zolpidem
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00079170

Locations
United States, Maryland
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
Bethesda, Maryland, United States, 20892-1182
Sponsors and Collaborators
Investigators
Study Chair: Michael C. Cox, PharmD NCI - Medical Oncology Branch
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00079170     History of Changes
Obsolete Identifiers: NCT00076193
Other Study ID Numbers: CDR0000355083, NCI-04-C-0084
Study First Received: March 8, 2004
Last Updated: June 18, 2013
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
male breast cancer
recurrent breast cancer
stage IIIA breast cancer
stage IIIB breast cancer
stage IIIC breast cancer
stage IV breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Docetaxel
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on October 19, 2014